IDEXX Laboratories Company Profile (NASDAQ:IDXX)

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Medical Equipment & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:IDXX
  • CUSIP: 45168D10
  • Web: www.idexx.com
Capitalization:
  • Market Cap: $14.99685 billion
  • Outstanding Shares: 88,123,000
Average Prices:
  • 50 Day Moving Avg: $164.54
  • 200 Day Moving Avg: $152.49
  • 52 Week Range: $92.52 - $173.01
P/E:
  • Trailing P/E Ratio: 61.71
  • Foreward P/E Ratio: 47.86
  • P/E Growth: 3.20
Sales & Book Value:
  • Annual Revenue: $1.82 billion
  • Price / Sales: 8.06
  • Book Value: ($0.84) per share
  • Price / Book: -198.27
Profitability:
  • EBIDTA: $449.79 million
  • Net Margins: 13.47%
  • Return on Equity: -706.91%
  • Return on Assets: 15.74%
Debt:
  • Debt-to-Equity Ratio: -8.05%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 629,230 shs.
  • Beta: 0.48
  • Short Ratio: 3.4
 
Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its board has authorized a stock repurchase plan on Sunday, June 4th 2017, which authorizes the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Friday, April, 28th. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.61 by $0.16. The company earned $462 million during the quarter, compared to analysts' expectations of $455.10 million. IDEXX Laboratories had a net margin of 13.47% and a negative return on equity of 706.91%. The firm's quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.51 EPS. View IDEXX Laboratories' Earnings History.

When will IDEXX Laboratories make its next earnings announcement?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for IDEXX Laboratories.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

6 analysts have issued 12-month target prices for IDEXX Laboratories' shares. Their predictions range from $118.00 to $185.00. On average, they expect IDEXX Laboratories' stock price to reach $161.00 in the next year. View Analyst Ratings for IDEXX Laboratories.

What are analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
  • Jay Mazelsky, Executive Vice President
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
  • William T. End, Lead Independent Director
  • Bruce L. Claflin, Independent Director
  • Rebecca M. Henderson Ph.D., Independent Director
  • Daniel M. Junius, Independent Director
  • Lawrence D. Kingsley, Independent Director

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.40%), Ardevora Asset Management LLP (0.27%), First Quadrant L P CA (0.24%), Howland Capital Management LLC (0.22%), Bourne Lent Asset Management Inc. (0.13%) and Harvey Investment Co. LLC (0.12%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Capital Investment Services of America Inc., Ardevora Asset Management LLP, Russell Investments Group Ltd., First Quadrant L P CA, Meeder Asset Management Inc., Howland Capital Management LLC, Bourne Lent Asset Management Inc. and Headinvest LLC. Company insiders that have sold IDEXX Laboratories stock in the last year include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Acadian Asset Management LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Mn Services Vermogensbeheer B.V., Oregon Public Employees Retirement Fund, Bedrijfstakpensioenfonds Voor DE Media PNO, National Pension Service and Aperio Group LLC. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $166.55.


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $161.00 (3.33% downside)

Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Stifel NicolausReiterated RatingBuy$185.00LowView Rating Details
6/13/2017Canaccord GenuityReiterated RatingBuy$180.00LowView Rating Details
5/31/2017AegisInitiated CoverageSell$118.00LowView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
9/29/2016Bank of America CorporationReiterated RatingNeutralN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
4/1/2016CL KingInitiated CoverageNeutralN/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/28/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for IDEXX Laboratories (NASDAQ:IDXX)
Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Earnings History by Quarter for IDEXX Laboratories (NASDAQ IDXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017        
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.83
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.72$0.76$0.74
Q4 20173$0.59$0.67$0.64
(Data provided by Zacks Investment Research)

Dividends

Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 89.04%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.00View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
Source:
DateHeadline
finance.yahoo.com logoA Stock That Is Like Switzerland And Another One With A Very Compelling Razor/Razor Blade Model
finance.yahoo.com - July 25 at 8:04 PM
americanbankingnews.com logoIDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 25 at 3:06 PM
finance.yahoo.com logoETFs with exposure to IDEXX Laboratories, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 11:28 PM
prnewswire.com logoDaily Technical Summary Reports on Healthcare Stocks -- Valeant Pharma, Palatin Technologies, AMAG Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - July 24 at 8:17 AM
americanbankingnews.com logoIDEXX Laboratories, Inc. (NASDAQ:IDXX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 23 at 11:50 PM
nasdaq.com logoIDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards? - Nasdaq
www.nasdaq.com - July 21 at 4:17 PM
finance.yahoo.com logoThese Non-Tech Companies Are Investing In An AI Future
finance.yahoo.com - July 21 at 4:17 PM
finance.yahoo.com logoIDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
finance.yahoo.com - July 21 at 4:17 PM
americanbankingnews.com logo Brokerages Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $500.78 Million
www.americanbankingnews.com - July 20 at 10:00 AM
americanbankingnews.com logoHead to Head Contrast: IDEXX Laboratories (NASDAQ:IDXX) & Heska Corporation (HSKA)
www.americanbankingnews.com - July 18 at 8:24 PM
prnewswire.com logoIDEXX Laboratories Elects Stuart M. Essig to Board of Directors - PR Newswire (press release)
www.prnewswire.com - July 17 at 8:45 PM
finance.yahoo.com logoIDEXX Laboratories Elects Stuart M. Essig to Board of Directors
finance.yahoo.com - July 17 at 8:45 PM
americanbankingnews.com logoHead-To-Head Survey: IDEXX Laboratories (IDXX) & Heska Corporation (HSKA)
www.americanbankingnews.com - July 16 at 10:29 PM
americanbankingnews.com logoHead to Head Survey: IDEXX Laboratories (IDXX) and Heska Corporation (HSKA)
www.americanbankingnews.com - July 16 at 8:12 PM
americanbankingnews.com logoStifel Nicolaus Reiterates Buy Rating for IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - July 15 at 11:18 AM
americanbankingnews.com logoIDEXX Laboratories (IDXX) versus Heska Corporation (HSKA) Head to Head Comparison
www.americanbankingnews.com - July 15 at 10:08 AM
americanbankingnews.com logoComparing Heska Corporation (HSKA) & IDEXX Laboratories (IDXX)
www.americanbankingnews.com - July 15 at 9:02 AM
nasdaq.com logoFriday Sector Leaders: Healthcare, Utilities - Nasdaq
www.nasdaq.com - July 15 at 1:22 AM
finance.yahoo.com logoETFs with exposure to IDEXX Laboratories, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 1:22 AM
finance.yahoo.com logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : July 13, 2017
finance.yahoo.com - July 14 at 3:27 AM
americanbankingnews.com logoCritical Survey: IDEXX Laboratories (IDXX) & Heska Corporation (HSKA)
www.americanbankingnews.com - July 11 at 2:10 PM
prnewswire.com logoIDEXX Laboratories to Release 2017 Second Quarter Financial ... - PR Newswire (press release)
www.prnewswire.com - July 10 at 7:43 PM
finance.yahoo.com logoIDEXX Laboratories to Release 2017 Second Quarter Financial Results
finance.yahoo.com - July 10 at 7:43 PM
americanbankingnews.com logoAnalyzing Heska Corporation (HSKA) and IDEXX Laboratories (NASDAQ:IDXX)
www.americanbankingnews.com - July 8 at 2:18 PM
americanbankingnews.com logoIDEXX Laboratories (NASDAQ:IDXX) & Heska Corporation (HSKA) Financial Contrast
www.americanbankingnews.com - July 6 at 4:26 PM
americanbankingnews.com logoIDEXX Laboratories, Inc. (NASDAQ:IDXX) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - July 5 at 8:38 PM
americanbankingnews.com logoIDEXX Laboratories, Inc. (IDXX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - June 30 at 9:39 AM
bizjournals.com logoGlobal biotech firm could create 100 Louisville jobs with new lab development
www.bizjournals.com - June 30 at 12:04 AM
americanbankingnews.com logoIDEXX Laboratories, Inc. (IDXX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 29 at 12:52 AM
finance.yahoo.com logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : June 28, 2017
finance.yahoo.com - June 28 at 7:21 PM
americanbankingnews.com logoContrasting Heska Corporation (HSKA) and IDEXX Laboratories (IDXX)
www.americanbankingnews.com - June 28 at 7:52 AM
nasdaq.com logoMedidata (MDSO), inVentiv Enter Into Multi-Year Partnership - Nasdaq
www.nasdaq.com - June 27 at 6:02 PM
finance.yahoo.com logoMedidata (MDSO), inVentiv Enter Into Multi-Year Partnership
finance.yahoo.com - June 27 at 6:02 PM
finance.yahoo.com logoIDEXX Laboratories Stock Could Just Be Heating Up
finance.yahoo.com - June 27 at 6:02 PM
americanbankingnews.com logoIDEXX Laboratories, Inc. (IDXX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 27 at 2:52 PM
nasdaq.com logoMerit Medical Embosphere Gets FDA de novo Classification - Nasdaq
www.nasdaq.com - June 27 at 5:50 AM
finance.yahoo.com logoMerit Medical Embosphere Gets FDA de novo Classification
finance.yahoo.com - June 26 at 7:38 PM
americanbankingnews.com logoHead to Head Comparison: IDEXX Laboratories (IDXX) versus Heska Corporation (HSKA)
www.americanbankingnews.com - June 25 at 7:54 AM
americanbankingnews.com logoZacks: Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $500.78 Million
www.americanbankingnews.com - June 24 at 8:48 AM
americanbankingnews.com logoIDEXX Laboratories, Inc. (IDXX) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - June 23 at 8:20 PM
americanbankingnews.com logoIDEXX Laboratories, Inc. (IDXX) Expected to Announce Earnings of $0.83 Per Share
www.americanbankingnews.com - June 22 at 6:36 PM
finance.yahoo.com logoPRA Health Hits a 52-Week High on Strategic Acquisitions
finance.yahoo.com - June 22 at 1:18 PM
finance.yahoo.com logoNeogen Offers NeoSeek Genomic Services to Ensure Food Safety
finance.yahoo.com - June 20 at 6:43 PM
finance.yahoo.com logoPRA Health (PRAH) Shares Rally on Partnership with Jumo
finance.yahoo.com - June 20 at 6:43 PM
finance.yahoo.com logoTransEnterix Sells Surgery System to Japanese University
finance.yahoo.com - June 16 at 6:42 PM
finance.yahoo.com logoVarian Showcases Halcyon System at DEGRO Meet, Stock Up
finance.yahoo.com - June 16 at 6:42 PM
finance.yahoo.com logoPacific Biosciences (PACB) Prices Offering of Common Stock
finance.yahoo.com - June 16 at 6:42 PM
finance.yahoo.com logoIDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : June 14, 2017
finance.yahoo.com - June 14 at 7:48 PM
seekingalpha.com logoIDEXX Laboratories (IDXX) Presents At The William Blair 2017 Growth Stock Conference - Slideshow
seekingalpha.com - June 14 at 11:29 AM
americanbankingnews.com logoBidaskClub Downgrades IDEXX Laboratories, Inc. (IDXX) to Buy
www.americanbankingnews.com - June 13 at 11:40 PM

Social

Chart

IDEXX Laboratories (IDXX) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff